Phase 4
N=22
Use of Platelet-rich Plasma (PRP) Therapy in Patients With Brittle Nail Syndrome
Nail Diseases
Bottom Line
View on ClinicalTrials.gov: NCT04941807 ↗Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Apr 2024
Primary outcome: Primary: Physician Global Improvement Assessment (PGIA) — 5; 2; 7; 1 Fingernails
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Platelet-rich plasma (Device); Platelet-poor plasma (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Weill Medical College of Cornell University
- Primary completion
- Apr 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Physician Global Improvement Assessment (PGIA) |
5; 2; 7; 1; 9; 2 | — |
| SECONDARY Change From Baseline in Qualify of Life, as Measured by the Modified Nail Psoriasis Quality of Life Scale (NPQ10) Between Baseline and Week 16 |
10 | — |
Summary
The purpose of this study is to assess the efficacy and safety of platelet-rich plasma therapy for brittle nail syndrome
Eligibility Criteria
Inclusion Criteria
- Patients who have been diagnosed with brittle nails
- Must understand and voluntarily sign an informed consent form
- Must be male or female and aged 18-95 years at time of consent
- Must be able to adhere to the study visit schedule and other protocol requirements
- A nail clipping with histopathology that is negative for the presence of dermatophyte infection
- Patient must present with at least a score of 2 on the PGA scale.
Exclusion Criteria
- Inability of the patient to provide written informed consent for any reason.
- Subject has psoriasis, lichen planus, dermatophyte infection or other confounding abnormalities that are severe enough to result in a clinically abnormal fingernail
- Use of any medication within 90 days prior to start of study
- Inability to abstain for nail polishes, nail gels during the study period
- Subject is pregnant or planning pregnancy.
Data sourced from ClinicalTrials.gov (NCT04941807). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.